Primm Pharma

Primm Pharma is a biotechnology company specializing in the development of long-acting injectable drug delivery systems. Based in Milan, Italy, the company utilizes its proprietary P-Spheres microsphere technology to create sustained-release formulations of existing drugs, primarily focusing on oncology and endocrinology. Its lead program is a six-month formulation of triptorelin for the treatment of prostate cancer and endometriosis. The company's technology platform allows for the precise control of drug release profiles, reducing dosing frequency and improving patient compliance. In 2016, Primm Pharma was acquired by Luye Pharma Group to strengthen its global portfolio in advanced drug delivery systems.